



# Synthesis, $\alpha$ -amylase inhibition and molecular docking study of bisindolymethane sulfonamide derivatives

Muhammad Taha<sup>1</sup> · Tayyaba Noreen<sup>2,3</sup> · Syahrul Imran<sup>3,4</sup> · Fasial Nawaz<sup>2</sup> · Sridevi Chigurupati<sup>5</sup> · Manikandan Selvaraj<sup>6</sup> · Fazal Rahim<sup>7</sup> · Nor Hadiani Ismail<sup>3,4</sup> · Ashok Kumar<sup>8</sup> · Ashik Mosaddik<sup>1</sup> · Abdullah M. Alghamdi<sup>9</sup> · Yousif Abdulrahman nasser alqahtani<sup>10</sup> · Abdulaziz Abdulrahman nasser alqahtani<sup>11</sup>

Received: 17 January 2019 / Accepted: 20 August 2019 / Published online: 5 September 2019  
© Springer Science+Business Media, LLC, part of Springer Nature 2019

## Abstract

We have synthesized nineteen (**1–19**) bisindolymethane sulfonamide analogs, characterized by different spectroscopic techniques such as <sup>1</sup>HNMR and EI-MS and tested for  $\alpha$ -amylase inhibitory potential. All compounds showed excellent to moderate degree of  $\alpha$ -amylase inhibitory potential with IC<sub>50</sub> values ranging between 1.192 ± 0.51 to 3.057 ± 0.18  $\mu$ M as equated with standard acarbose (IC<sub>50</sub> values 0.83 ± 0.36  $\mu$ M). Among the series, six analogs such as **1**, **4**, **5**, **6**, **10**, and **14** showed potent  $\alpha$ -amylase inhibition with IC<sub>50</sub> values 1.747 ± 0.2, 1.208 ± 0.15, 1.192 ± 0.51, 1.858 ± 0.08, 1.358 ± 0.27 and 1.527 ± 0.17  $\mu$ M, respectively, as equated with standard acarbose. The structure-activity relationship based upon different substituents on phenyl part. Molecular docking studies performed to recognize the binding interaction of the most active compounds.

**Supplementary information** The online version of this article (<https://doi.org/10.1007/s00044-019-02431-4>) contains supplementary material, which is available to authorized users.

✉ Muhammad Taha  
mtaha@iau.edu.sa

<sup>1</sup> Department of Clinical Pharmacy, Institute for Research and Medical Consultations (IRMC), University of Dammam, Dammam 31441, Saudi Arabia

<sup>2</sup> Department of Chemistry, University of Wah, Quaid Avenue, Wah Cantt 47000, Pakistan

<sup>3</sup> Atta-ur-Rahman Institute for Natural Product Discovery, Universiti Teknologi MARA (UiTM), Puncak Alam Campus, 42300 Bandar Puncak Alam, Selangor, Malaysia

<sup>4</sup> Faculty of Applied Science, UiTM Shah Alam, 40450 Shah Alam, Selangor D.E., Malaysia

<sup>5</sup> Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraidah 51452, Saudi Arabia

<sup>6</sup> School of Engineering, Monash University (Malaysia Campus), Bandar Sunway 47500, Malaysia

<sup>7</sup> Department of Chemistry, Hazara University, Mansehra 21300 Khyber Pakhtunkhwa, Pakistan


<sup>8</sup> Department of Pharmaceutical Chemistry, Faculty of Pharmacy, AIMST University, Semeling, 08100 Bedong, Kedah, Malaysia

<sup>9</sup> Management Information Systems, College of Applied Studies and Community Service, Imam Abdulrahman Bin Faisal University, P.O. Box. 1982, Dammam 31441, Saudi Arabia

<sup>10</sup> King Fahad specialist hospital in Dammam, (general surgery resident), Dammam 31441, Saudi Arabia

<sup>11</sup> College of Medicine Imam Abdulrahman Bin Faisal University, P.O. Box. 1982, Dammam 31441, Saudi Arabia

## Graphical Abstract



**Keywords** Synthesis · Bisindolylmethane sulfonamide ·  $\alpha$ -Amylase Inhibitory Potential · Molecular docking · SAR

## Introduction

The most of energy in the body is achieved by intake of starch. The most useful enzymes which break down starch to use are alpha-amylases in salivary, pancreatic as well as alpha-glucosidases presents in small intestinal (Liu et al. 2011).

$\alpha$ -Amylase catalyze the breaking down of starch to shorter useful sugar by cleavage of internal  $\alpha$ -D-(1-4) glycosidic bonds that yielded  $\alpha$ -anomeric products. The main products of  $\alpha$ -amylase action are the dextrans as well as oligosaccharides (Sales et al. 2012; Sivaramakrishnan et al. 2006).

The excessive intake of starchy food is main culprit for developing diabetic II (Kwon et al. 2006; Tadera et al. 2006). In diabetic II the sugar level in the blood arises uncontrollably which causes hyperglycemic situations in body. The main treatment for hyperglycemia to induce insulin production from the  $\beta$ -cells of pancreatic islets. Other way stops the generation of sugar degradation by two main enzymes  $\alpha$ -amylase and  $\alpha$ -glucosidase (Jarald et al. 2008). So,  $\alpha$ -amylase inhibitors are considered as most important tool to control the diabetic II (Adisakwattana et al. 2011).

The indole compounds considered as most important class for medicinal and bioorganic chemistry research (Sundberg 1996; Pelletier 1999). Indole two cyclic frameworks allows to have rigid skeleton which is useful for the

interactions with enzymes or receptors (Shaheen et al. 1999). The indole compounds are reported in natural products as well as biologically (Ali et al. 2013; Nencki 1874; Asghari et al. 2014; Stöckly 1881). Additionally, indole is reported as antioxidant and showed very interesting results various types of cancer (Nematollahi and Hedayatfar 2011).

Indole derivatives showed very interesting results  $\alpha$ -amylase inhibitory as well as alpha-glucosidases in recent past (Taha et al. 2019; Gollapalli et al. 2018; Javid et al. 2018)

Our group is uninterruptedly working on synthesis of biological compounds (Aziz et al. 2014; Musharraf et al. 2012; Anouar et al. 2013; Khan et al. 2011; Khan et al. 2010; Khan et al. 2009; Khan et al. 2008) and hydrazones (Khan et al. 2014; Taha et al. 2013; Taha et al. 2014). Due to wide range application of indole, here in this study we are going to report  $\alpha$ -amylase inhibitory potential and molecular docking analysis of bisindolylmethane sulfonamide derivatives.

## Experimental

### General method

Avance Bruker 600 MHz was used for NMR experiments. Elemental analysis results got by Carlo Erba Strumentazione-Mod-1106, Italy. Finnigan MAT-311A (Germany) recorded EI-MS.

### Synthetic Procedure for the synthesis of bisindolymethane ester (I)

1,2-dimethyl indole 20 mmol was refluxed with 10 mmol of methyl 4-formylbenzoate in the presence of acetic acid as solvent for 6 h. The reaction checked by TLC and the reaction mixture was poured in cold water, the ppt formed was filtered and washed with cold water.

### Synthetic procedure for the synthesis of 4-(bis(1,2-dimethyl-1H-indol-3-yl) methyl) benzohydrazide (II)

Bisindolymethane ester refluxed with mixture of hydrazine-hydrate/methanol for 4 h. The reaction completion confirmed by TLC and after completion of reaction the reaction mixture was dried by rotary evaporator, the ppt formed was filtered and washed with cold water.

Yield: 88%. M.p.194 °C; Brown crystal; <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>): δ 8.33 (s, 1H, HN), 7.94–7.84 (m, 2H), 7.76 (dd, *J* = 7.5, 1.4 Hz, 2H), 7.49 (d, *J* = 7.5 Hz, 2H), 7.42 (s, 2H), 7.34 (td, *J* = 7.4, 1.5 Hz, 2H), 7.26 (td, *J* = 7.4, 1.5 Hz, 2H), 5.73 (s, 1H), 4.08 (s, 2H, NH<sub>2</sub>), 3.76 (s, 6H 2xCH<sub>3</sub>), 2.36 (s, 6H 2xCH<sub>3</sub>); δ <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>):δ 164.9, 141.5, 137.3, 137.3, 132.6, 132.6, 131.2, 113.1, 129.2, 129.2, 127.7, 127.7, 127.4, 127.4, 122.2, 122.2, 120.1, 120.1, 119.0, 119.0, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS: *m/z* calcd for C<sub>28</sub>H<sub>28</sub>N<sub>4</sub>O, [M]<sup>+</sup> 436.2263 found: 436.2067; Anal. Calcd for, C<sub>28</sub>H<sub>28</sub>N<sub>4</sub>O, C, 77.04; H, 6.46; N, 12.83; Found: C, 77.06; H, 6.47; N, 12.85.

### General Procedure for the synthesis of bisindolymethane sulfonamide derivatives (1–19)

Equimolar amount of 4-(bis(1,2-dimethyl-1H-indol-3-yl) methyl) benzohydrazide reacted with different aryl sulfonyl chloride in the presence of pyridine to give us bisindolymethane sulfonamide derivatives. After reaction completion, the reaction mixture was poured in cold water and filtered, washed and dried.

### *N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-4-chlorobenzenesulfonylhydrazide (1)

Yield: 80%. M.p.195 °C; Light purple; <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>):δ 12.42 (s, 1H, NH), 11.62 (s, 1H, NH), 7.80 (d, *J* = 8.1 Hz, 2H), 7.72 (d, *J* = 7.0 Hz, 2H), 7.51 (t, *J* = 8.0 Hz, 2H), 7.40 (d, *J* = 8.0 Hz, 2H), 7.31 (d, *J* = 7.9 Hz, 2H), 7.13 (t, *J* = 7.0 Hz, 2H), 6.93 (t, *J* = 7.0 Hz, 2H), 6.84 (s, 2H), 5.98 (s, 1H), 3.74 (s, 6H); 3.29 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>):δ 164.9, 141.5, 137.8, 137.5, 137.3, 137.3, 132.6, 132.6, 131.2, 129.2, 129.2, 129.2, 129.2, 128.7, 128.7, 127.7, 127.7, 127.4, 127.4, 122.2, 122.2,

120.1, 120.1, 119.0, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS: *m/z* calcd for C<sub>34</sub>H<sub>31</sub>ClN<sub>4</sub>O<sub>3</sub>S, [M]<sup>+</sup> 610.1805; Found 610.1828; [M+2]<sup>+</sup> 612. 1760: Anal. Calcd for C<sub>34</sub>H<sub>31</sub>ClN<sub>4</sub>O<sub>3</sub>S, C, 66.82; H, 5.11; N, 9.17; Found C, 66.81; H, 5.09; N, 9.18.

### *N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-4-nitrobenzenesulfonylhydrazide (2)

Yield: 83%. M.p.195 °C; Brown powder; <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>):δ 12.56 (s, 1H, NH), 12.15 (s, 1H, NH), 7.96 (d, *J* = 7.0 Hz, 2H), 7.80 (d, *J* = 7.5 Hz, 2H), 7.50 (d, *J* = 8.0 Hz, 2H), 7.43 (d, *J* = 8.0 Hz, 2H), 7.31 (d, *J* = 7.5 Hz, 2H), 7.10 (t, *J* = 7.0 Hz, 2H), 6.90 (t, *J* = 7.5 Hz, 2H), 6.89 (s, 2H), 5.96 (s, 1H), 3.73 (s, 6H), 2.65 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>):δ 164.9, 151.6, 145.8, 141.5, 137.3, 137.3, 132.6, 132.6, 131.2, 129.2, 129.2, 128.2, 128.2, 127.7, 127.7, 127.4, 127.4, 122.2, 122.2, 121.4, 121.4, 120.1, 120.1, 119.0, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS: *m/z* calcd for C<sub>34</sub>H<sub>31</sub>N<sub>5</sub>O<sub>5</sub>S, [M]<sup>+</sup> 621.2046; Found 621.2061; Anal. Calcd for, C<sub>34</sub>H<sub>31</sub>N<sub>5</sub>O<sub>5</sub>S, C, 65.68; H, 5.03; N, 11.26; Found C, 65.67; H, 5.02; N, 11.28.

### *N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-2-nitrobenzenesulfonylhydrazide (3)

Yield: 83%. M.p.138 °C; Light purple; <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>):δ 12.30 (s, 1H, NH), 11.73 (s, 1H, NH), 7.79–7.67 (m, 5H), 7.31 (dd, *J* = 7.5, 1.6 Hz, 2H), 7.28–7.17 (m, 4H), 7.08 (dd, *J* = 7.5, 1.5 Hz, 2H), 6.98 (td, *J* = 7.4, 1.6 Hz, 2H), 5.38 (d, *J* = 1.2 Hz, 1H), 3.62 (s, 6H), 2.32 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>):δ 164.9, 145.4, 141.5, 137.3, 137.3, 135.2, 134.4, 132.9, 132.6, 132.6, 131.2, 129.2, 129.2, 128.2, 127.7, 127.7, 127.4, 127.4, 122.2, 122.2, 121.4, 120.1, 120.1, 119.0, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS: *m/z* calcd for C<sub>34</sub>H<sub>31</sub>ClN<sub>4</sub>O<sub>3</sub>S, [M]<sup>+</sup> 621.2046; Found 621.2038; Anal. Calcd for C<sub>34</sub>H<sub>31</sub>N<sub>5</sub>O<sub>5</sub>S, C, 65.68; H, 5.03; N, 11.26; Found C, 65.66; H, 5.02; N, 11.25.

### *N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-4-fluorobenzenesulfonylhydrazide (4)

Yield: 83%. M.p.166 °C; purple; <sup>1</sup>H NMR (600 MHz, DMSO-*d*<sub>6</sub>):δ 12.30 (s, 1H, NH), 11.82 (s, 1H, NH), 7.83–7.76 (m, 4H), 7.52 (d, *J* = 7.0 Hz, 2H), 7.42 (d, *J* = 8.0 Hz, 2H), 7.31 (d, *J* = 7.5 Hz, 2H), 7.30–7.24 (m, 2H), 7.11 (t, *J* = 7.0 Hz, 2H), 6.92 (t, *J* = 7.0 Hz, 2H), 5.92 (s, 1H), 3.75 (s, 6H), 2.91 (s, 6H); <sup>13</sup>C NMR (150 MHz, DMSO-*d*<sub>6</sub>):δ 166.1 (d, *J*<sub>(C-F)</sub> = 160 Hz), 164.9, 141.5, 137.3, 137.3, 135.3, 132.6, 132.6, 131.2, 129.2, 128.9, 128.9, 128.9, 127.7, 127.7, 127.4, 127.4, 122.2, 122.2,

120.1, 120.1, 119.0, 119.0, 115.8, 115.8, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS:  $m/z$  calcd for  $C_{34}H_{31}FN_4O_3S$ ,  $[M]^+$  594.2101; Found 594.2117; Anal. Calcd for  $C_{34}H_{31}FN_4O_3S$ , C, 68.67; H, 5.25; N, 9.42; Found C, 68.69; H, 5.26; N, 9.41.

***N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-4-hydroxybenzenesulfonohydrazide (5)**

Yield: 83%. M.p.151 °C; Light purple;  $^1H$  NMR (600 MHz, DMSO- $d_6$ ): $\delta$  11.58 (s, 2H, 2xNH), 9.92 (s, 1H, OH), 7.78 (d,  $J = 8.0$  Hz, 2H), 7.52 (d,  $J = 8.0$  Hz, 2H), 7.45 (d,  $J = 7.5$  Hz, 2H), 7.37 (d,  $J = 8.0$  Hz, 2H), 7.30 (d,  $J = 7.5$  Hz, 2H), 7.10 (t,  $J = 7.0$  Hz, 2H), 6.90 (t,  $J = 7.0$  Hz, 2H), 6.80 (d,  $J = 80$  Hz, 2H), 5.92 (s, 1H), 3.72 (s, 6H) 2.60 (s, 6H);  $^{13}C$  NMR (150 MHz, DMSO- $d_6$ ): $\delta$  164.9, 163.9, 141.5, 137.3, 137.3, 132.6, 132.6, 132.0, 131.2, 129.2, 129.2, 128.3, 128.3, 127.7, 127.7, 127.4, 127.4, 122.2, 122.2, 120.1, 120.1, 119.0, 119.0, 114.6, 114.6, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS:  $m/z$  calcd for  $C_{34}H_{32}N_4O_4S$ ,  $[M]^+$  592.2144; Found 592.2247; Anal. Calcd for  $C_{34}H_{32}N_4O_4S$ , C, 68.90; H, 5.44; N, 9.45; Found C, 68.92; H, 5.47; N, 9.46.

***N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-4-bromobenzenesulfonohydrazide (6)**

Yield: 83%. M.p.131 °C; purple;  $^1H$  NMR (600 MHz, DMSO- $d_6$ ): $\delta$  11.82 (s, 1H, NH), 9.71(s, 1H, NH), 7.72 (t,  $J = 7.0$  Hz, 2H), 7.56 (d,  $J = 7.0$  Hz, 2H), 7.41 (d,  $J = 8.0$  Hz, 2H), 7.30 (d,  $J = 7.0$  Hz, 2H), 7.30–7.21 (m, 4H), 7.10 (t,  $J = 7.0$  Hz, 2H), 6.96 (t,  $J = 7.5$  Hz, 2H), 5.95 (s, 1H), 3.74 (s, 6H), 2.45 (s, 3H);  $^{13}C$  NMR (150 MHz, DMSO- $d_6$ ): $\delta$  164.9, 141.5, 138.7, 137.3, 137.3, 132.6, 132.6, 132.0, 132.0, 131.2, 129.5, 129.5, 129.2, 129.2, 127.7, 127.7, 127.4, 127.4, 126.3, 122.2, 122.2, 120.1, 120.1, 119.0, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS:  $m/z$  calcd for  $C_{34}H_{31}BrN_4O_3S$ ,  $[M]^+$  654.1300; Found 654.1314;  $[M + 2]^+$  656.1288; Anal. Calcd for  $C_{34}H_{31}BrN_4O_3S$ , C, 62.29; H, 4.77; N, 8.55; Found C, 62.30; H, 4.75; N, 8.54.

***N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-2-methylbenzenesulfonohydrazide (7)**

Yield: 86%. M.p.141 °C; purple;  $^1H$  NMR (600 MHz, DMSO- $d_6$ ): $\delta$  12.23 (s, 1H, NH), 11.63 (s, 1H, NH), 7.86 (s, 1H), 7.72–7.66 (m, 2H), 7.62–7.58 (m, 2H), 7.47–7.30 (m, 4H), 7.21 (dd,  $J = 7.4, 1.6$  Hz, 3H), 7.04–6.95 (m, 4H), 5.94 (s, 1H) 3.75 (s, 6H), 2.45 (s, 6H), 2.24 (s, 3H);  $^{13}C$  NMR (150 MHz, DMSO- $d_6$ ): $\delta$  164.9, 141.5, 139.0, 137.3, 137.3, 136.6, 132.6, 132.6, 131.9, 131.2, 129.4, 129.2, 129.2, 127.7, 127.7, 127.4, 127.4, 127.2, 126.1, 122.2, 122.2,

120.1, 120.1, 119.0, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 16.4, 6.2, 6.2; HR-ESI-MS:  $m/z$  calcd for  $C_{35}H_{34}N_4O_3S$ ,  $[M]^+$  590.2352; Found 590.2350; Anal. Calcd for  $C_{35}H_{34}N_4O_3S$ , C, 71.16; H, 5.80; N, 9.48; Found C, 71.14; H, 5.81; N, 9.49.

***N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-3-nitrobenzenesulfonohydrazide (8)**

Yield: 90%. M.p.178 °C; purple;  $^1H$  NMR (600 MHz, DMSO- $d_6$ ): $\delta$  12.77 (s, 1H), 12.07 (s, 1H), 8.21 (d,  $J = 7.5$  Hz, 1H), 7.86–7.80 (m, 2H), 7.62 (t,  $J = 7.0$  Hz, 1H), 7.52 (dd,  $J = 7.5$  Hz, 2H), 7.43–7.36 (m, 4H), 7.22 (dd,  $J = 7.5$  Hz, 2H), 7.13–7.05 (m, 4H), 5.95 (s, 1H), 3.79 (s, 6H), 2.78 (s, 6H);  $^{13}C$  NMR (150 MHz, DMSO- $d_6$ ): $\delta$  164.9, 148.7, 141.5, 140.6, 137.3, 137.3, 133.4, 132.6, 132.6, 131.2, 130.0, 129.2, 129.2, 127.7, 127.7, 127.4, 127.4, 124.3, 122.2, 122.2, 120.6, 120.1, 120.1, 119.0, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS:  $m/z$  calcd for  $C_{34}H_{31}N_5O_5S$ ,  $[M]^+$  621.2046; Found 621.2037; Anal. Calcd for  $C_{34}H_{31}N_5O_5S$ , C, 65.68; H, 5.03; N, 11.26; Found C, 65.69; H, 5.04; N, 11.27.

***N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-4-methylbenzenesulfonohydrazide (9)**

Yield: 94%. M.p. 150 °C; purple;  $^1H$  NMR (600 MHz, DMSO- $d_6$ ): $\delta$  11.70 (s, 1H), 11.06 (s, 1H), 7.85–7.79 (m, 2H), 7.67–7.61 (m, 2H), 7.40–7.23 (m, 8H), 7.14 (dd,  $J = 7.4, 1.6$  Hz, 2H), 7.04 (td,  $J = 7.4, 1.5$  Hz, 2H), 5.93 (s, 1H), 3.68 (s, 6H), 2.68 (s, 6H), 2.17 (s, 3H);  $^{13}C$  NMR (150 MHz, DMSO- $d_6$ ): $\delta$  164.9, 141.6, 141.5, 137.3, 137.3, 136.7, 132.6, 132.6, 131.2, 129.4, 129.4, 129.2, 129.2, 127.7, 127.7, 127.4, 127.4, 127.2, 127.2, 122.2, 122.2, 120.1, 120.1, 119.0, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 24.3, 6.2, 6.2; HR-ESI-MS:  $m/z$  calcd for  $C_{34}H_{31}ClN_4O_3S$ ,  $[M]^+$  590.2352; Found 590.2349; Anal. Calcd for  $C_{35}H_{34}N_4O_3S$ , C, 71.16; H, 5.80; N, 9.48; Found C, 71.15; H, 5.81; N, 9.47.

***N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-3,4-dichlorobenzenesulfonohydrazide (10)**

Yield: 93%. M.p.150 °C; purple;  $^1H$  NMR (600 MHz, DMSO- $d_6$ ): $\delta$  11.50 (s, 1H, NH), 9.55 (s, 1H, NH), 7.62 (d,  $J = 7.0$  Hz, 2H), 7.40 (dd,  $J = 7.5$  Hz, 2H), 7.38–7.27 (m, 4H), 7.18 (dd,  $J = 7.5, 1.5$  Hz, 2H), 6.98–6.89 (m, 4H), 6.78 (d,  $J = 7.5$  Hz, 1H), 5.918 (s, 1H), 3.72 (s, 6H), 2.21 (s, 6H);  $^{13}C$  NMR (150 MHz, DMSO- $d_6$ ): $\delta$  164.9, 141.5, 139.2, 137.3, 137.3, 136.6, 133.7, 132.6, 132.6, 131.2, 130.6, 129.2, 129.2, 128.0, 127.7, 127.7, 127.4, 127.4, 126.8, 122.2, 122.2, 120.1, 120.1, 119.0, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS:

m/z calcd for  $C_{34}H_{31}ClN_4O_3S$ ,  $[M]^+$  644.1416; Found 644.1421;  $[M+1]^+$  645.1452;  $[M+2]^+$  646.1382; Anal. Calcd for  $C_{34}H_{30}Cl_2N_4O_3S$ , C, 63.25; H, 4.68; N, 8.68; Found C, 63.23; H, 4.67; N, 8.65.

***N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-2,4-dichlorobenzenesulfonylhydrazide (11)**

Yield: 83%. M.p.124 °C; purple;  $^1H$  NMR (600 MHz, DMSO- $d_6$ ): $\delta$  11.75 (s, 1H, NH), 11.50 (s, 1H, NH), 7.46 (dd,  $J = 7.0, 2.0$  Hz, 1H), 7.41 (dd,  $J = 7.0, 2.0$  Hz, 2H), 7.32 (d,  $J = 7.0$  Hz, 1H), 6.95–6.84 (m, 4H), + 6.38 (dd,  $J = 7.5, 1.5$  Hz, 1H), 6.28 (td,  $J = 7.4, 1.5$  Hz, 2H), 5.98 (s, 1H), 3.82 (s, 6H), 2.51 (s, 6H);  $^{13}C$  NMR (150 MHz, DMSO- $d_6$ ): $\delta$  164.9, 141.5, 138.9, 137.8, 137.3, 137.3, 132.9, 132.6, 132.6, 131.2, 130.7, 130.1, 129.2, 129.2, 127.7, 127.7, 127.4, 127.4, 127.3, 122.2, 122.2, 120.1, 120.1, 119.0, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS: m/z calcd for  $C_{34}H_{30}Cl_2N_4O_3S$ ,  $[M]^+$  644.1416; Found 644.1411;  $[M+1]^+$  645.1445;  $[M+2]^+$  646.1378; Anal. Calcd for  $C_{34}H_{30}Cl_2N_4O_3S$ , C, 63.25; H, 4.68; N, 8.68; Found C, 63.25; H, 4.68; N, 8.67.

***N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-2,5-dichlorobenzenesulfonylhydrazide (12)**

Yield: 93%. M.p.136 °C; purple;  $^1H$  NMR (600 MHz, DMSO- $d_6$ ): $\delta$  12.04 (s, 1H, NH), 10.70 (s, 1H, NH), 7.60 (d,  $J = 7.0$  Hz, 2H), 7.40 (dd,  $J = 7.5, 2.0$  Hz, 2H), 7.38 (d,  $J = 7.5$  Hz, 2H), 7.17–7.06 (m, 3H), 6.90–6.78 (m, 6H), 5.97 (s, 1H), 3.81 (s, 6H), 2.70 (s, 6H);  $^{13}C$  NMR (150 MHz, DMSO- $d_6$ ): $\delta$  164.9, 141.5, 141.1, 137.3, 137.3, 133.5, 132.7, 133.5, 132.7, 132.6, 132.6, 131.2, 130.6, 129.6, 129.2, 129.2, 128.0, 127.7, 127.7, 127.4, 127.4, 122.2, 122.2, 120.1, 120.1, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS: m/z calcd for  $C_{34}H_{30}Cl_2N_4O_3S$ ,  $[M]^+$  644.1416; Found 644.1403;  $[M+1]^+$  645.1455;  $[M+2]^+$  646.1374; Anal. Calcd for  $C_{34}H_{30}Cl_2N_4O_3S$ , C, 63.25; H, 4.68; N, 8.68; Found C, 63.24; H, 4.69; N, 8.66.

***N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-2,3-dichlorobenzenesulfonylhydrazide (13)**

Yield: 99%. M.p.133 °C; purple;  $^1H$  NMR (600 MHz, DMSO- $d_6$ ): $\delta$  12.10 (s, 1H, NH), 11.20 (s, 1H, NH), 7.95 (dd,  $J = 7.5, 2.0$  Hz, 2H), 7.50 (dd,  $J = 7.0, 2.0$  Hz, 2H), 7.36–7.29 (m, 4H), 7.20 (dd,  $J = 7.5, 1.5$  Hz, 2H), 6.93–6.84 (m, 4H), 6.80 (dd,  $J = 7.0, 1.5$  Hz, 2H), 5.95 (s, 1H), 3.84 (s, 6H), 2.73 (s, 6H);  $^{13}C$  NMR (150 MHz, DMSO- $d_6$ ): $\delta$  164.9, 141.5, 141.1, 137.3, 137.3, 133.7, 133.5, 132.6, 132.6, 131.2, 131.2, 129.2, 129.2, 128.6, 127.7, 127.7, 127.4, 127.4, 126.8, 122.2, 122.2, 120.1,

120.1, 119.0, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS: m/z calcd for  $C_{34}H_{30}Cl_2N_4O_3S$ ,  $[M]^+$  644.1416; Found 644.1407;  $[M+1]^+$  645.1447;  $[M+2]^+$  646.1380; Anal. Calcd for  $C_{34}H_{30}Cl_2N_4O_3S$ , C, 63.25; H, 4.68; N, 8.68; Found C, 63.24; H, 4.66; N, 8.67.

***N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-3,5-dichlorobenzenesulfonylhydrazide (14)**

Yield: 91%. M.p. 122 °C; purple;  $^1H$  NMR (600 MHz, DMSO- $d_6$ ): $\delta$  11.62 (s, 1H, NH), 9.42 (s, 1H, NH), 7.62 (dd,  $J = 7.5, 2.0$  Hz, 2H), 7.55 (dd,  $J = 7.0, 2.0$  Hz, 2H), 7.49 (d,  $J = 7.0$  Hz, 2H), 7.20 (dd,  $J = 7.5, 1.5$  Hz, 2H), 6.92–6.84 (m, 4H), 6.62 (d,  $J = 7.5$  Hz, 2H), 6.31 (s, 1H), 5.92 (s, 1H), 3.84 (s, 6H), 2.73 (s, 6H);  $^{13}C$  NMR (150 MHz, DMSO- $d_6$ ): $\delta$  164.9, 142.5, 141.5, 137.3, 137.3, 136.0, 136.0, 133.6, 132.6, 132.6, 131.2, 129.2, 129.2, 127.7, 127.7, 127.7, 127.7, 127.4, 127.4, 122.2, 122.2, 120.1, 120.1, 119.0, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS: m/z calcd for  $C_{34}H_{30}Cl_2N_4O_3S$ ,  $[M]^+$  644.1416; Found 644.1419;  $[M+1]^+$  645.1458;  $[M+2]^+$  646.1386; Anal. Calcd for  $C_{34}H_{30}Cl_2N_4O_3S$ , C, 63.25; H, 4.68; N, 8.68; Found C, 63.23; H, 4.66; N, 8.67.

***N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-2,4,5-trichlorobenzenesulfonylhydrazide (15)**

Yield: 91%. M.p.122 °C; purple;  $^1H$  NMR (600 MHz, DMSO- $d_6$ ): $\delta$  11.73 (s, 1H, NH), 10.65 (s, 1H), 7.54 (dd,  $J = 7.5, 2.0$  Hz, 2H), 7.31–7.20 (m, 4H), 7.19 (dd,  $J = 7.5, 2.0$  Hz, 2H), 6.91 (d,  $J = 7.0$  Hz, 2H), 6.84 (t,  $J = 7.0$  Hz, 2H), 6.81(s, 1H), 6.32 (s, 1H), 5.92 (s, 1H), 3.75 (s, 6H), 2.74 (s, 6H);  $^{13}C$  NMR (150 MHz, DMSO- $d_6$ ): $\delta$  164.9, 141.5, 139.2, 138.0, 137.3, 137.3, 132.6, 132.6, 132.1, 131.8, 131.0, 131.2, 129.4, 129.2, 129.2, 127.7, 127.7, 127.4, 127.4, 122.2, 122.2, 120.1, 120.1, 119.0, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS: m/z calcd for  $C_{34}H_{29}Cl_3N_4O_3S$ ,  $[M]^+$  678.1026; Found 678.1031;  $[M+1]^+$  679.1054;  $[M+2]^+$  680.0990;  $[M+3]^+$  681.1026;  $[M+4]^+$  682.0962; Anal. Calcd for  $C_{34}H_{29}Cl_3N_4O_3S$ , C, 60.05; H, 4.30; N, 8.24; Found C, 60.03; H, 4.32; N, 8.25.

***N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-2-fluorobenzenesulfonylhydrazide (16)**

Yield: 84%. M.p.129 °C; purple;  $^1H$  NMR (600 MHz, DMSO- $d_6$ ): $\delta$  11.94 (s,1H, NH), 11.25 (s, 1H, NH), 7.91 (dd,  $J = 7.4, 2.0$  Hz, 2H), 7.52–7.46 (m, 2H), 7.41–7.31 (m, 4H), 7.31–7.20 (m, 4H), 7.16 (dd,  $J = 7.0, 2.0$  Hz, 2H), 6.91 (td,  $J = 7.0, 2.0$  Hz, 2H), 5.91 (s, 1H), 3.80 (s, 6H), 2.74 (s, 6H);  $^{13}C$  NMR (150 MHz, DMSO- $d_6$ ): $\delta$  164.9 (d,  $J_{(C-F)} =$

190 Hz), 158.3, 141.5, 137.3, 137.3, 133.6, 132.6, 132.6, 131.2, 129.2, 129.2, 128.9, 127.7, 127.7, 127.4, 127.4, 126.3, 124.7, 122.2, 122.2, 120.1, 120.1, 119.0, 119.0, 115.8, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS:  $m/z$  calcd for  $C_{34}H_{31}FN_4O_3S$ ,  $[M]^+$  594.2101; Found 594.2117; Anal. Calcd for  $C_{34}H_{31}FN_4O_3S$ , C, 68.67; H, 5.25; N, 9.42; Found C, 68.68; H, 5.26; N, 9.41.


#### *N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-2-chlorobenzenesulfonylhydrazide (17)

Yield: 84%. M.p. 113 °C; purple;  $^1H$  NMR (600 MHz, DMSO- $d_6$ ):  $\delta$  11.73 (s, 1H, NH), 11.20 (s, 1H, NH), 7.92–7.86 (m, 3H), 7.52 (dd,  $J = 7.5, 2.0$  Hz, 2H), 7.41 (d,  $J = 7.5$  Hz, 2H), 7.22–7.16 (m, 3H), 7.18 (dd,  $J = 7.5, 2.0$  Hz, 2H), 6.91 (dd,  $J = 7.5, 2.0$  Hz, 2H), 6.85 (d,  $J = 7.5$  Hz, 2H), 5.91 (s, 1H), 3.75 (s, 6H), 2.34 (s, 6H);  $^{13}C$  NMR (150 MHz, DMSO- $d_6$ ):  $\delta$  164.9, 141.5, 139.7, 137.3, 137.3, 133.4, 132.6, 132.6, 131.5, 131.2, 129.2, 129.2, 129.2, 128.7, 127.7, 127.7, 127.4, 127.4, 127.2, 122.2, 122.2, 120.1, 120.1, 119.0, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS:  $m/z$  calcd for  $C_{34}H_{31}ClN_4O_3S$ ,  $[M]^+$  610.1805; Found 610.1826;  $[M+2]^+$  612.1764; Anal. Calcd for  $C_{34}H_{31}ClN_4O_3S$ , C, 66.82; H, 5.11; N, 9.17; Found C, 66.81; H, 5.10; N, 9.16.

#### *N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-2,4-dinitrobenzenesulfonylhydrazide (18)

Yield: 87%. m.p. 164 °C; purple;  $^1H$  NMR (600 MHz, DMSO- $d_6$ ):  $\delta$  11.93 (s, 1H, NH), 11.65 (s, 1H, NH), 7.52 (dd,  $J = 7.5, 2.0$  Hz, 2H), 7.43–7.38 (m, 3H), 7.35 (d,  $J = 7.5$  Hz, 2H), 7.12 (d,  $J = 7.0$  Hz, 2H), 6.93 (dd,  $J = 7.5, 2.0$  Hz, 2H), 6.88 (d,  $J = 7.5$  Hz, 2H), 6.48–6.40 (m, 2H), 5.92 (s, 1H), 3.75 (s, 6H), 2.34 (s, 6H);  $^{13}C$  NMR (150 MHz, DMSO- $d_6$ ):  $\delta$  164.9, 152.5, 146.3, 141.5, 140.5, 137.3, 137.3, 132.6, 132.6, 131.2, 129.2, 129.2, 129.1, 127.7, 127.7, 127.5, 127.4, 127.4, 122.2, 122.2, 120.1, 120.1, 119.0, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS:  $m/z$  calcd for  $C_{34}H_{30}N_6O_7S$ ,  $[M]^+$  666.1897; Found 666.1913; Anal. Calcd for  $C_{34}H_{30}N_6O_7S$ , C, 61.25; H, 4.54; N, 12.61; Found C, 61.26; H, 4.55; N, 12.62.

**Scheme 1** Synthesis of bisindolylmethane sulfonamide derivatives 1–19



#### *N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)-3-bromobenzenesulfonylhydrazide (19)

Yield: 89%. m.p. 125 °C; purple;  $^1H$  NMR (600 MHz, DMSO- $d_6$ ):  $\delta$  11.69 (s, 1H, NH), 9.49 (s, 1H, NH), 7.77 (dd,  $J = 7.5, 2.0$  Hz, 2H), 7.65 (d,  $J = 7.5$  Hz, 2H), 7.32–7.07 (m, 8H), 6.87 (td,  $J = 7.4, 2.0$  Hz, 2H), 6.77 (dd,  $J = 7.0$  Hz, 2H), 5.92 (s, 1H), 3.76 (s, 6H), 2.70 (s, 6H);  $^{13}C$  NMR (150 MHz, DMSO- $d_6$ ):  $\delta$  164.9, 141.9, 141.5, 137.3, 137.3, 134.9, 132.6, 132.6, 131.3, 131.2, 129.2, 129.2, 129, 127.7, 127.7, 127.4, 127.4, 126.3, 123.4, 122.2, 122.2, 120.1, 120.1, 119.0, 119.0, 113.1, 113.1, 111.1, 111.1, 42.7, 35.9, 35.9, 6.2, 6.2; HR-ESI-MS:  $m/z$  calcd for  $C_{34}H_{31}BrN_4O_3S$ ,  $[M]^+$  654.1300; Found 654.1313;  $[M+2]^+$  656.1280; Anal. Calcd for  $C_{34}H_{31}BrN_4O_3S$ , C, 62.29; H, 4.77; N, 8.55; Found C, 62.30; H, 4.78; N, 8.53.

#### $\alpha$ -Amylase inhibitory assay

Zhang and coworkers method (Zhang et al. 2011) was used with small modification for  $\alpha$ -Amylase inhibitory activity. We used sample protocol as we used in our previous publications (Adegboye et al. 2018; Bale et al. 2018; Salar et al. 2017).


#### Molecular docking studies with amylase

We used sample protocol as we used in our previous publications (Noreen et al. 2017; Imran et al. 2017; Taha et al. 2017).

## Results and discussion

### Chemistry

Synthesis of *N'*-(4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzoyl)arylsulfonylhydrazide is carried out by the reaction of equimolar 4-(bis(1,2-dimethyl-1H-indol-3-yl)methyl)benzohydrazide and aryl sulfonyl chloride with pyridine. The reaction mixture was dried and washed with cold water. The crude product recrystallized and categorized by different spectroscopy methods (Scheme 1 and Table 1).

**Table 1** Bis-indolylmethane sulfonamide analogs (**1–19**) synthesis and  $\alpha$ -amylase inhibitory potential

S. No	R	IC <sub>50</sub> ±SEM <sup>a</sup>
1		1.747±0.2
2		3.057±0.18
3		2.101±0.05
4		1.208±0.15
5		1.192±0.51
6		1.858±0.08
7		2.485±0.11
8		3.008±0.02
9		2.174±0.05
10		1.358±0.27
11		2.108±0.08
12		2.037±0.06
13		2.206±0.14
14		1.527±0.17
15		2.161±0.07
16		2.517±0.06
17		2.169±0.04
18		2.372±0.04
19		2.392±0.02
<b>Acarbose</b> (standard drug)		0.83±0.36

## In vitro $\alpha$ -amylase inhibitory potential

We have synthesized nineteen (1–19) bisindolylmethane sulfonamide analogs. They were evaluated for  $\alpha$ -amylase inhibitory potential. They showed  $\alpha$ -amylase inhibition with  $IC_{50}$  values ranging between  $1.192 \pm 0.51$  to  $3.057 \pm 0.18 \mu\text{M}$  as compared with standard acarbose  $IC_{50}$  values  $0.83 \pm 0.36 \mu\text{M}$ . Among the series, six compounds such as **1**, **4**, **5**, **6**, **10**, and **14** showed potent  $\alpha$ -amylase inhibition with  $IC_{50}$  values  $1.747 \pm 0.2$ ,  $1.208 \pm 0.15$ ,  $1.192 \pm 0.51$ ,  $1.858 \pm 0.08$ ,  $1.358 \pm 0.27$  and  $1.527 \pm 0.17 \mu\text{M}$ , respectively, when compared with the standard acarbose. All other compounds such as **2**, **3**, **7**, **8**, **9**, **11**, **12**, **13**, **15**, **16**, **17**, **18**, and **19** having  $IC_{50}$  values  $3.057 \pm 0.18$ ,  $2.101 \pm 0.05$ ,  $2.485 \pm 0.11$ ,  $3.008 \pm 0.02$ ,  $2.174 \pm 0.05$ ,  $2.108 \pm 0.08$ ,  $2.037 \pm 0.06$ ,  $2.206 \pm 0.14$ ,  $2.161 \pm 0.07$ ,  $2.517 \pm 0.06$ ,  $2.169 \pm 0.04$ ,  $2.372 \pm 0.04$  and  $2.392 \pm 0.02 \mu\text{M}$ , respectively, showed good to moderate  $\alpha$ -amylase inhibition.

The most potent compound is compound **5** with  $IC_{50}$  value  $1.192 \pm 0.51 \mu\text{M}$  having *para*-hydroxy substituent at the phenyl part. The great potential of this compound is seems to be due to the hydroxy group which is electron-donating. The second most active analog among the series is compound **4** with  $IC_{50}$  value  $1.208 \pm 0.15 \mu\text{M}$  having


*para*-fluoro at the phenyl part while the third most active analog among the series is compound **10** with  $IC_{50}$  value  $1.358 \pm 0.27 \mu\text{M}$  having *meta*, *para*-chloro at the phenyl part. Both of the substituents are electron-withdrawing groups which might play some role in these inhibitions (Fig. 1).

If we compare analog **10** having  $IC_{50}$  value  $1.358 \pm 0.27 \mu\text{M}$  with analog **11** having  $IC_{50}$  value  $2.108 \pm 0.08 \mu\text{M}$ , analog **12** having  $IC_{50}$  value  $2.037 \pm 0.06 \mu\text{M}$ , analog **13** having  $IC_{50}$  value  $2.206 \pm 0.14 \mu\text{M}$  and analog **14** with  $IC_{50}$  value  $1.527 \pm 0.17 \mu\text{M}$ , all five analogs have chloro groups, with different pattern of substitution in them which authorized that the difference in position of substituents momentarily affect the inhibitory potentials of the compounds (Fig. 2).


Similarly compound **2**, a 4-nitro analog ( $IC_{50} = 3.057 \pm 0.18 \mu\text{M}$ ) if compared with other nitro compounds like **3**, a 2-nitro analog ( $IC_{50} = 2.101 \pm 0.05 \mu\text{M}$ ) and **8**, a 3-nitro analog ( $IC_{50} = 3.008 \pm 0.02 \mu\text{M}$ ). The little bit difference in potential of these analogs showed that position of substituent also play role in this inhibition (Fig. 3).

If we compare compound **7**, a 2-methyl analog having  $IC_{50}$  value  $2.485 \pm 0.11 \mu\text{M}$  with compound **9**, a 4-methyl analog having  $IC_{50}$  value  $2.174 \pm 0.05 \mu\text{M}$ . The compound **9** was found to be superior (Fig. 4).

**Fig. 1** Comparison between compounds **4**, **5**, and **10**



**Fig. 2** Comparison of structure-activity relationship between compounds **10**, **11**, **12**, **13**, and **14**




### Docking study


The docking studies show the binding mode of the bisindolylmethane sulfonamide derivatives bound to the active site of the amylase enzyme. Here in this paper, we only show the top most four compounds binding mode.

Figure 5a shows the binding mode of the compound **5** is the most active among the bisindolylmethane sulfonamide derivatives. The phenon oxygen and the hydrazide NH forms hydrogen bond with Glu240 and Tyr151, respectively. Further, the phenol ring and one of the bisindole ring forms  $\pi$ - $\pi$  stacking with Trp151 and Trp58, respectively. In

**Fig. 3** Comparison of structure-activity relationship between compounds 2, 3, and 8



**Fig. 4** Comparison of structure-activity relationship between compounds 7 and 9




addition interactions the bisindole ring forms hydrophobic interaction with Trp59, Tyr62, Leu162, Leu165, Trp357 and the phenol ring forms similar interactions with Ile235, Leu237, and Ala307.

In the case of the compound 4, the complex was stabilized by the  $\pi$ - $\pi$  stacking of the the fluorophenyl ring with His201, the bisindole rings with Trp58, Tyr62 and with Trp59, respectively. Next the presence of the  $\pi$ -cationic


interaction of the His299 with one of the bisindole ring and additional hydrophobic interaction with Leu165 and Trp357. Moreover, the presence of hydrophobic contacts of the fluorophenyl ring with residues such as Tyr151, Leu162, Ala198, Val 234 and Ile235, stabilizes the complex furthermore (Fig. 5b).

The compound 10 shows that the hydrazide NH forms hydrogen bond with Try151. While there is stable  $\pi$ - $\pi$



**Fig. 5** Illustrates the predicted binding modes of active sulfonyl derivatives. Binding modes of **a** compound **5**, **b** compound **4**. Key residues are represented in spear and labeled. The potential of H-bond

interaction are represented by magenta color arrow,  $\pi$ - $\pi$  interactions are shown in green color lines and cation-pi interactions are shown in red color lines. Compounds are shown in line form



**Fig. 6** Illustrates the predicted binding modes of active sulfonyl derivatives. Binding modes of **a** compound **10**, **b** compound **14**. Key residues are represented in spear and labeled. The potential of H-bond

interaction are represented by magenta color arrow,  $\pi$ - $\pi$  interactions are shown in green color lines. Compounds are shown in line form

stacking between dichlorophenyl ring with His201 and similar  $\pi$ - $\pi$  interaction is also observed between one of the bisindole ring with the His305. Moreover the complex was also found to have hydrophobic contacts of the dichlorophenyl ring with Leu162, Ala198, Val234, and Ile235. Similarly, the bisindole ring forms non polar contacts with Trp58, Trp59, Tyr62, Leu165, and Trp357 (Fig. 6a).

The Fig. 6b shows the binding mode of the compound **14**, where the dichloro ring forms  $\pi$ - $\pi$  stacking with His201 and one of the bisindole ring forms similar interaction with His305. In addition the dichlorophenyl ring also forms nonpolar interaction with Tyr151, Leu162, Ala198, and Val234. Finally, the bisindole ring forms hydrophobic contacts with Trp58, Trp59, Tyr62, Leu165, and Trp357, respectively.

## Conclusion

In this study, we have synthesized nineteen bisindolylmethane sulfonamide analogs and screened for  $\alpha$ -amylase inhibitory activity. All analogs showed a variable degree of  $\alpha$ -amylase inhibition with  $IC_{50}$  values ranging between  $1.192 \pm 0.51$  to  $3.057 \pm 0.18 \mu\text{M}$  when compared with standard acarbose having  $IC_{50}$  values  $0.83 \pm 0.36 \mu\text{M}$ . Among the series, six compounds such as **1**, **4**, **5**, **6**, **10** and **14** showed potent  $\alpha$ -amylase inhibition while all other remaining compounds showed good to moderate  $\alpha$ -amylase inhibition. The structure-activity relationship has reveals that difference of substituents nature and position on phenyl part of compounds effect their potential greatly.

**Acknowledgements** We would like to thank IRMC and Imam Abdulrahman Bin Faisal University for Lab facilities.

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## References

- Adegboye AA, Khan KM, Salar U, Aboaba SA, Chigurupati S, Fatima I, Taha M, Wadood A, Mohammad JI, Khan H, Perveen S (2018) 2-Aryl benzimidazoles: synthesis, in vitro  $\alpha$ -amylase inhibitory activity, and molecular docking study. *Eur J Med Chem* 150:248–260
- Adisakwattana S, Lerdsuwankij O, Poputtachai U, Minipun A, Suparprom C (2011) Inhibitory activity of cinnamon bark species and their combination effect with acarbose against intestinal  $\alpha$ -glucosidase and pancreatic  $\alpha$ -amylase. *Plant Foods Hum Nutr* 66:143–148
- Ali S, Ali N, Ahmad DB, Pradhan V, Farooqui M (2013) Chemistry and biology of indoles and indazoles: a mini review. *Med Chem* 13:1792–1800
- Anouar EH, Raweh S, Bayach I, Taha M, Baharudin MS, Meo FD, Hasan MH, Adam A, Ismail NH, Weber JF, Trouillas P (2013) Antioxidant properties of phenolic Schiff bases: structure-activity relationship and mechanism of action. *J Comput Aided Mol Des* 27:951–964
- Asghari A, Ameri M, Radmannia S, Rajabi M, Bakherad M, Nematollahi D (2014) None-catalyst and clean synthesis of symmetric and asymmetric indoles from electrochemical oxidation of 4-aminophenol and p-phenylenediamine in the presence of malononitrile in green media. *J Electro Chem* 733:47–52
- Aziz AN, Taha M, Ismail NH, Anouar EH, Yousuf S, Jamil W, Awang K, Ahmat N, Khan KM, Kashif SM (2014) Synthesis, crystal structure, DFT studies and evaluation of the antioxidant activity of 3,4-dimethoxybenzenamine schiff bases. *Molecules* 19:8414–8433
- Bale AT, Khan KM, Salar U, Chigurupati S, Fasina T, Ali F, Wadood A, Taha M, Nanda SS, Ghufuran M, Perveen S (2018) Chalcones and bis-chalcones: as potential  $\alpha$ -amylase inhibitors; synthesis, in vitro screening, and molecular modelling studies. *Bioorg Chem* 79:179–189
- Gollapalli M, Taha M, Ullah H, Nawaz M, AlMuqarrabun LMR, Rahim F, Qureshi F, Mosaddik A, Ahmat N, Khan KM (2018) Synthesis of bis-indolylmethane sulfonylhydrazides derivatives as potent  $\alpha$ -glucosidase inhibitors. *Bioorg Chem* 80:112–120
- Imran S, Taha M, Selvaraj M, Ismail NH, Chigurupati S, Mohammad JI (2017) Synthesis and biological evaluation of indole derivatives as  $\alpha$ -amylase inhibitor. *Bioorg Chem* 73:121–128
- Jarald E, Joshi SB, Jain DC (2008) Diabetes and herbal medicines. *Iran J Pharma Ther* 7:97–106
- Javid MT, Rahim F, Taha M, Nawaz M, Wadood A, Ali M, Mosaddik A, Shah SAA, Farooq RK (2018) Synthesis, SAR elucidations and molecular docking study of newly designed isatin based oxadiazole analogs as potent inhibitors of thymidine phosphorylase. *Bioorg Chem* 79:323–333
- Khan KM, Taha M, Naz F, Khan M, Rahim F, Samreen, Perveen S, Choudhary MI (2011) Synthesis and in vitro leishmanicidal activity of disulfide derivatives. *Med Chem* 7:704–710
- Khan KM, Taha M, Rahim F, Ali M, Jamil W, Perveen S, Choudhary MI (2010) An improved method for the synthesis of disulfides by periodic acid and sodium hydrogen sulfite in water. *Lett Org Chem* 7:244
- Khan KM, Taha M, Ali M, Perveen S (2009) A mild and alternative approach towards symmetrical disulfides using  $H_3IO_5/NaHSO_3$  combination. *Lett Org Chem* 6:319–320
- Khan KM, Ali M, Taha M, Perveen S, Choudhary MI, Voelter W (2008) An expedient and selective approach towards disulfides using sodium bromate/sodium hydrogen sulfite reagent. *Lett Org Chem* 5:432–434
- Khan KM, Naz F, Taha M, Khan A, Perveen S, Choudhary MI, Voelter W (2014) Synthesis and in vitro urease inhibitory activity of *N,N'*-disubstituted thioureas. *Eur J Med Chem* 74:314–323
- Kwon YI, Vattem DA, Shetty K (2006) Evaluation of clonal herbs of Lamiaceae species for management of diabetes and hypertension. *Asia Pacif J Clin Nutr* 15:107–118
- Liu T, Song L, Wang H, Huang D (2011) A high-throughput assay for quantification of starch hydrolase inhibition based on turbidity measurement. *J Agric Food Chem* 59:9756–9762
- Musharraf SG, Bibi A, Shahid N, Najam-ul-Haq M, Khan M, Taha M, Mughal UR, Khan KM (2012) Acylhydrazide and isatin schiff bases as alternate UV laser desorption ionization (LDI) matrices for low molecular weight (LMW) peptides analysis. *Am J Ana Chem* 3:779–789
- Nencki M (1874) On a combination of sulphocarbamide with ethyl oxalate. *Deut Chem Ges Ber* vii:779–780
- Noreen T, Taha M, Imran S, Chigurupati S, Rahim F, Selvaraj M, Ismail NH, Mohammad JI, Ullah H, Nawaz F, Irshad M, Ali M (2017) Synthesis of alpha amylase inhibitors based on privileged indole scaffold. *Bioorg Chem* 72:248–255
- Nematollahi D, Hedayatfar V (2011) Diversity in electrochemical oxidation of dihydroxybenzenes in the presence of 1-methylindole. *J Chem Sci* 123:709–717
- Pelletier SW (1999) Alkaloids: Chemical and Biological Perspectives. Springer-Verlag, New York, NY, Springer
- Sales PM, de Souza PM, Simeoni LA, Magalhães PDO, Silveira D (2012)  $\alpha$ -Amylase inhibitors: a review of raw material and isolated compounds from plant source. *J Pharm Pharmace Sci* 15:141–183
- Salar U, Khan KM, Chigurupati S, Taha M, Wadood A, Vijayabalan S, Ghufuran M, Perveen S (2017) New hybrid hydrazinylthiazole substituted chromones: as potential  $\alpha$ -amylase inhibitors and radical (DPPH & ABTS) scavengers. *Sci Rep* 7:16980
- Shaheen RM, Davis DW, Liu W (1999) Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastases and induces tumor and endothelial cell apoptosis. *Cancer Res* 59:5412–5416
- Sivaramakrishnan S, Gangadharan D, Nampoothiri KM, Soccol CR, Pandey A (2006)  $\alpha$ -Amylases from microbial sources—An overview on recent developments. *Food Techn Biotech* 44:173–184
- Stöckly F (1881) Zur Kenntniss der Fäulnisprodukte des Gehirns. *J Prakt Chem* 24:17–24
- Sundberg RJ (1996) The Chemistry of Indoles. Academic Press, New York, NY
- Tadera K, Minami Y, Takamatsu K, Matsuoka T (2006) Inhibition of alpha-glucosidase and alpha-amylase by flavonoids. *J Nutr Sci Vitam* 52:149–153
- Taha M, Naz H, Rasheed S, Ismail NH, Rahman AA, Yousuf S, Choudhary MI (2014) Synthesis of 4-methoxybenzoylhydrazones and evaluation of their antiglycation activity. *Molecules* 19:1286–1301
- Taha M, Ismail NH, Jamil W, Yousuf S, Jaafar FM, Ali MI, Kashif SM, Hussain E (2013) Synthesis, Evaluation Of Antioxidant Activity And Crystal Structure Of 2,4-dimethylbenzoylhydrazones. *Molecules* 18:10912–10929

- Taha M, Javid MT, Imran S, Selvaraj M, Chigurupati S, Ullah H, Rahim F, Khan F, Mohammad JI (2017) Synthesis and study of the  $\alpha$ -amylase inhibitory potential of thiazole quinoline derivatives. *Bioorg Chem* 74:179–186
- Taha M, Irshad M, Imran S, Rahim F, Selvaraj M, Almandil NB, Ibrahim M (2019) Thiazole based carbohydrazide derivatives as  $\alpha$ -amylase inhibitor and their molecular docking study. *Hetero Chem* 2019:7502347
- Zhang L, Hogan S, Li J, Sun S, Canning C, Zheng SJ, Zhou K (2011) Grape skin extract inhibits mammalian intestinal  $\alpha$ -glucosidase activity and suppresses postprandial glycemic response in streptozocin-treated mic. *Food Chem* 126:466–471